Literature DB >> 1477316

Chronic lactic acidosis in a patient with acquired immunodeficiency syndrome and mitochondrial myopathy: biochemical studies.

R Gopinath1, M Hutcheon, S Cheema-Dhadli, M Halperin.   

Abstract

A 30-yr-old man with acquired immunodeficiency syndrome treated with zidovudine developed biopsy-proven mitochondrial myopathy. Chronic lactic acidosis (lactate, 10 +/- 1 mmol/L) persisted for more than 5 wk. Liver function tests were normal, but the concentration of lactose rose to 16.1 mmol/L when 500 mmol of ethanol was infused. The concentration of lactose rose by only 1.5 mmol/L with maximally tolerated exercise. If this mitochondrial lesion compromised flux through the electron transport system, increased turnover of ATP with exercise should have exacerbated the degree of lactic acidosis because of increased need to regenerate ATP via glycolysis. Two possible explanations will be discussed: first, there was both a rapid rate of production of lactic acid in affected muscles in conjunction and an equally rapid rate of removal by uninvolved organs. Second, there was a low net rate of production of lactic acid in involved muscles despite the exercise.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1477316     DOI: 10.1681/ASN.V361212

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  3 in total

1.  Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment.

Authors:  P Scalfaro; J J Chesaux; P A Buchwalder; J Biollaz; J L Micheli
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

Review 2.  Electrolyte and acid-base disorders associated with AIDS: an etiologic review.

Authors:  M A Perazella; E Brown
Journal:  J Gen Intern Med       Date:  1994-04       Impact factor: 5.128

Review 3.  Lactic acidosis in HIV infected patients: a systematic review of published cases.

Authors:  A Arenas-Pinto; A D Grant; S Edwards; I V D Weller
Journal:  Sex Transm Infect       Date:  2003-08       Impact factor: 3.519

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.